STC1010

STC1010 is a therapeutic candidate under development by Staidson Pharma and its subsidiaries, including Staidson Hongkong and Staidson Biopharmaceutical. The asset is primarily identified as a monoclonal antibody targeting Nerve Growth Factor (NGF) for the treatment of chronic pain, currently in Phase 2 clinical trials. However, company pipeline documentation also lists STC1010 as a small molecule in Phase 1 development for Parkinson's disease and in preclinical development for depression. The anti-NGF mechanism is designed to block the interaction of NGF with its receptors, thereby reducing the sensitization of pain-sensing neurons. The discrepancy in modality and indication across pipeline entries suggests that STC1010 may be a shared code or reflects inconsistencies in the source's reporting of distinct programs.